Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Assessment of Annual Rate Changes of Intraarticular Tissue Measurements in Hemophilic Joints Experiencing Acute Bleeding Using the Joint Activity Damage Exam (JADE) Ultrasound Protocol

Parthiv V Sheth, Michael Glenzer, Isaac Nwi-Mozu, Peter Aguero, Bruno U.K. Steiner, DPT, RMSK, Cindy Bailey, Doris V. Quon, Rebecca Kruse-Jarres, Annette von Drygalski

Blood (2024) 144 (Supplement 1): 3965.

https://doi.org/10.1182/blood-2024-199852

Published: 2024

Journal Articles

Improved Joint Health in the Phase 3 HOPE-B Trial of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B over 36 Months of Follow up

Rebecca Kruse-Jarres, Bruce Ewenstein, Paul E. Monahan, Nicholas Galante, Nathalie W.D. Jansen, Sean Gill, Niamh O'Connell

Blood (2024) 144 (Supplement 1): 3580.

https://doi.org/10.1182/blood-2024-201395

Published: 2024

Journal Articles

How I treat von Willebrand disorders in older adults

Jacqueline N. Poston, Rebecca Kruse-Jarres

Blood (2024) 143 (3): 197–204.

https://doi.org/10.1182/blood.2022018534

Published: 2024

Journal Articles

Heterotopic Ossification in Hemophilia: A Multi-Center Case Series

Bruno U.K. Steiner, DPT, RMSK, Mark A Krimmel, Eric Y Chang, Merel A Timmer, Grace Hernandez, Jeffrey Kallberg, Osman Khan, Lorene Schmaderer, Fred Loeffler, Stacie Akins, Tiffany Kaltenmark, Stacey Cave, Jessica Ovans, Rebecca Kruse-Jarres

Blood (2023) 142 (Supplement 1): 1248.

https://doi.org/10.1182/blood-2023-173700

Published: 2023

Journal Articles

Neurocognitive Assessment of Adults with Sickle Cell Disease: A Descriptive Study

Olubusola Oluwole, Kleber Yotsumoto Fertrin, Rebecca Kruse-Jarres

Blood (2021) 138 (Supplement 1): 4172.

https://doi.org/10.1182/blood-2021-145808

Published: 2021

Journal Articles

Emicizumab for the Treatment of Acquired Hemophilia a: A Multicenter US Case Series

Jacqueline N. Poston, Kadhim Al-Banaa, Annette von Drygalski, Aric D. Parnes, Christopher E Walsh, James F Wu, Craig M. Kessler, Maissaa Janbain, Lynn M Malec, Rebecca Kruse-Jarres

Blood (2021) 138 (Supplement 1): 496.

https://doi.org/10.1182/blood-2021-148040

Published: 2021

Journal Articles

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Blood (2021) 137 (16): 2231–2242.

https://doi.org/10.1182/blood.2020009217

Published: 2021

Includes: Supplemental data

Journal Articles

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Steven W. Pipe, MD, Michael Recht, MD PhD, Nigel S. Key, MD, Frank W.G. Leebeek, MD PhD, Giancarlo Castaman, MD, Susan U. Lattimore, R.N., Paul Van Der Valk, Kathelijne Peerlinck, MD PhD, Michiel Coppens, MD, Niamh O'Connell, MD PhD, John Pasi, MB, ChB, PhD FRCP, FRCPath, FRCPCH, Peter Kampmann, MD, Karina Meijer, MD PhD, Annette von Drygalski, MD Pharm D, Guy Young, MD, Cedric Hermans, MDMRCP,PhD, Jan Astermark, MD PhD, Robert Klamroth, MD PhD, Richard S. Lemons, MD, Nathan Visweshwar, MD, Shelley Crary, MD MS, Rashid Kazmi, MBBS, Emily Symington, Miguel A. Escobar, MD, Esteban Gomez, MD, Rebecca Kruse-Jarres, MD, Adam Kotowski, MD, Doris Quon, MD PhD, Michael Wang, MD, Allison P. Wheeler, MD, Eileen K Sawyer, PhD, Stephanie Verweij, BSc, Valerie Colletta, MSc, Naghmana Bajma, MD, Robert Gut, MD PhD, Wolfgang A. Miesbach, MD PhD

Blood (2020) 136 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2020-143560

Published: 2020

Journal Articles

Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)

Blood (2020) 136 (Supplement 1): 3–5.

https://doi.org/10.1182/blood-2020-137438

Published: 2020

Journal Articles

Risk of Hypertension in Hemophilia Patients with a History of Inhibitors

Anna Ter-Zakarian, Richard Barnes, PhD MPH, Rebecca Kruse-Jarres, MD MPH, Doris Quon, MD PhD, Shannon Jackson, MD FRCPC, Linda Sun, MD, Annette von Drygalski, MD PharmD, RMSK

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136133

Published: 2020

Journal Articles

Validity of Quantitative Measurements By the Joint Tissue Examination and Damage Exam (JADE) with Musculoskeletal Ultrasound for the Longitudinal Assessment of Hemophilic Arthropathy

Akram Mesleh Shayeb, MD, Richard Barnes, PhD MPH, Nicolas Gallastegui Crestani, MD, Cris Hanacek, BS, Peter Aguero, PT, DPT, Andres Flores, MS, ATC, CES, Rebecca Kruse-Jarres, MD, Bruno Steiner, PT, DPT, LMT, RMSK, Doris Quon, MD PhD, Cindy Bailey, DPT, OCS, SCS, ATC, Annette von Drygalski, MD PharmD, RMSK

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-143133

Published: 2020

Journal Articles

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

Guy Young, Ri Liesner, Tiffany Chang, Robert Sidonio, Jr, Johannes Oldenburg, Victor Jiménez-Yuste, Johnny Mahlangu, Rebecca Kruse-Jarres, Michael Wang, Marianne Uguen, Michelle Y. Doral, Lilyan Y. Wright, Christophe Schmitt, Gallia G. Levy, Midori Shima, Maria Elisa Mancuso

Blood (2019) 134 (24): 2127–2138.

https://doi.org/10.1182/blood.2019001869

Published: 2019

Includes: Supplemental data

Journal Articles

Quantitative Measurements of Hemophilic Joint Tissues By Point-of-Care Musculoskeletal Ultrasound Are Associated with Clinical and Functional Joint Outcome Parameters

Akram Mesleh Shayeb, MD, Richard Barnes, PhD MPH, Cris Hanacek, BS, Andres Flores, MS, ATC, CES, Rebecca Kruse-Jarres, MDMPH, Bruno Steiner, PT, DPT, LMT, RMSK, Doris Quon, MD PhD, Cindy Bailey, DPT, OCS, SCS, ATC, Annette von Drygalski, MD PharmD

Blood (2019) 134 (Supplement_1): 905.

https://doi.org/10.1182/blood-2019-129690

Published: 2019

Journal Articles

Patterns and Predictors of Emicizumab Adherence in People with Hemophilia

Ang Li, MD, Catlin Goodfriend, PharmD, John Sokol, PharmD, Rebecca Kruse-Jarres, MDMPH

Blood (2019) 134 (Supplement_1): 2178.

https://doi.org/10.1182/blood-2019-128083

Published: 2019

Journal Articles

Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study

Michael U. Callaghan, MD, Elina Asikanius, Michaela Lehle, Johannes Oldenburg, Johnny Mahlangu, Marianne Uguen, Sammy Chebon, Rebecca Kruse-Jarres, Victor Jimenez-Yuste, Midori Shima, MD PhD, Peter Trask, Christine L. Kempton, Craig M. Kessler, Gallia G. Levy, Elena Santagostino

Blood (2018) 132 (Supplement 1): 383.

https://doi.org/10.1182/blood-2018-99-118160

Published: 2018

Journal Articles

Urinary Cross-Linked Carboxyterminal Telopeptide Decreases with Resolution of Painful Vaso-Occlusive Crises in Adults with Sickle Cell Disease - Results from the Sickle Cell Pain Markers (SCPM) Study

Oyebimpe O. Adesina, MD, Isaac C. Jenkins, MS, Qian V. Wu, PhD, Ellen B. Fung, PhD RD, CCD, Kanika Mahajan, Rebecca Kruse-Jarres, MDMPH

Blood (2018) 132 (Supplement 1): 1100.

https://doi.org/10.1182/blood-2018-99-119801

Published: 2018

Journal Articles

Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia Α with Inhibitors: Results from the HAVEN 2 Study

Guy Young, Ri Liesner, Robert F. Sidonio, Jr., Johannes Oldenburg, Victor Jimenez-Yuste, Johnny Mahlangu, Rebecca Kruse-Jarres, Michael Wang, Tiffany Chang, Marianne Uguen, Michelle Doral, Christophe Schmitt, Gallia G. Levy, Midori Shima, MD PhD, Maria Elisa Mancuso

Blood (2018) 132 (Supplement 1): 632.

https://doi.org/10.1182/blood-2018-99-118153

Published: 2018

Journal Articles

How I treat type 2B von Willebrand disease

Rebecca Kruse-Jarres, Jill M. Johnsen

Blood (2018) 131 (12): 1292–1300.

https://doi.org/10.1182/blood-2017-06-742692

Published: 2018

Journal Articles

Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-Interventional Study (NIS) from a Real-World Setting

Johannes Oldenburg, Midori Shima, MDPhD, Rebecca Kruse-Jarres, Elena Santagostino, Johnny Mahlangu, Nives Selak Bienz, Sammy Chebon, Elina Asikanius, Gallia G. Levy

Blood (2017) 130 (Supplement 1): 1089.

https://doi.org/10.1182/blood.V130.Suppl_1.1089.1089

Published: 2017

Journal Articles

Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study

Maria Elisa Mancuso, Michael U. Callaghan, Rebecca Kruse-Jarres, Christine L Kempton, Jin Xu, Olivier Catalani, Elina Asikanius, Gallia G. Levy, Midori Shima, MDPhD, Guy Young, Johannes Oldenburg

Blood (2017) 130 (Supplement 1): 1071.

https://doi.org/10.1182/blood.V130.Suppl_1.1071.1071

Published: 2017

NARROW

Assessment of Annual Rate Changes of Intraarticular Tissue Measurements in Hemophilic Joints Experiencing Acute Bleeding Using the Joint Activity Damage Exam (JADE) Ultrasound Protocol

Improved Joint Health in the Phase 3 HOPE-B Trial of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B over 36 Months of Follow up

How I treat von Willebrand disorders in older adults

Heterotopic Ossification in Hemophilia: A Multi-Center Case Series

Neurocognitive Assessment of Adults with Sickle Cell Disease: A Descriptive Study

Emicizumab for the Treatment of Acquired Hemophilia a: A Multicenter US Case Series

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)

Risk of Hypertension in Hemophilia Patients with a History of Inhibitors

Validity of Quantitative Measurements By the Joint Tissue Examination and Damage Exam (JADE) with Musculoskeletal Ultrasound for the Longitudinal Assessment of Hemophilic Arthropathy

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

Quantitative Measurements of Hemophilic Joint Tissues By Point-of-Care Musculoskeletal Ultrasound Are Associated with Clinical and Functional Joint Outcome Parameters

Patterns and Predictors of Emicizumab Adherence in People with Hemophilia

Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study

Urinary Cross-Linked Carboxyterminal Telopeptide Decreases with Resolution of Painful Vaso-Occlusive Crises in Adults with Sickle Cell Disease - Results from the Sickle Cell Pain Markers (SCPM) Study

Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia Α with Inhibitors: Results from the HAVEN 2 Study

How I treat type 2B von Willebrand disease

Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-Interventional Study (NIS) from a Real-World Setting

Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only